Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Ott

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|July 14, 2004
Ten years of alendronate treatment for osteoporosis in postmenopausal womenSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|September 9, 2005
Letter re: alendronate in anorexia nervosaSusan M Ott
Annals of Internal Medicine|October 18, 2016
In postmenopausal women, oral but not transdermal estrogen was associated with increased risk for strokeSusan M Ott
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2008
Histomorphometric measurements of bone turnover, mineralization, and volumeSusan M Ott
Nephrology (Carlton, Vic.)|July 1, 2009
Review article: Bone density in patients with chronic kidney disease stages 4-5Susan M Ott
The New England Journal of Medicine|August 22, 2008
Osteoporosis in menSusan M Ott
Cleveland Clinic Journal of Medicine|September 3, 2011
What is the optimal duration of bisphosphonate therapy?Susan M Ott
JAAPA : Official Journal of the American Academy of Physician Assistants|September 21, 2013
Debating the duration of bisphosphonate therapySusan M Ott
Current Opinion in Rheumatology|May 29, 2019
Renal insufficiency and bone lossSusan M Ott
Kidney International|September 29, 2012
Bisphosphonate safety and efficacy in chronic kidney diseaseSusan M Ott
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|July 14, 2004
Ten years of alendronate treatment for osteoporosis in postmenopausal womenSusan M Ott
The Journal of Clinical Endocrinology and Metabolism|September 9, 2005
Letter re: alendronate in anorexia nervosaSusan M Ott
Annals of Internal Medicine|October 18, 2016
In postmenopausal women, oral but not transdermal estrogen was associated with increased risk for strokeSusan M Ott
Clinical Journal of the American Society of Nephrology : CJASN|November 15, 2008
Histomorphometric measurements of bone turnover, mineralization, and volumeSusan M Ott
Nephrology (Carlton, Vic.)|July 1, 2009
Review article: Bone density in patients with chronic kidney disease stages 4-5Susan M Ott
The New England Journal of Medicine|August 22, 2008
Osteoporosis in menSusan M Ott
Cleveland Clinic Journal of Medicine|September 3, 2011
What is the optimal duration of bisphosphonate therapy?Susan M Ott
JAAPA : Official Journal of the American Academy of Physician Assistants|September 21, 2013
Debating the duration of bisphosphonate therapySusan M Ott
Current Opinion in Rheumatology|May 29, 2019
Renal insufficiency and bone lossSusan M Ott
Kidney International|September 29, 2012
Bisphosphonate safety and efficacy in chronic kidney diseaseSusan M Ott
Pageof 9